SI3019240T1 - Protitelesa proti komplementnemu faktorju C1q in njihova uporaba - Google Patents

Protitelesa proti komplementnemu faktorju C1q in njihova uporaba

Info

Publication number
SI3019240T1
SI3019240T1 SI201432076T SI201432076T SI3019240T1 SI 3019240 T1 SI3019240 T1 SI 3019240T1 SI 201432076 T SI201432076 T SI 201432076T SI 201432076 T SI201432076 T SI 201432076T SI 3019240 T1 SI3019240 T1 SI 3019240T1
Authority
SI
Slovenia
Prior art keywords
antibodies
complement factor
complement
factor
Prior art date
Application number
SI201432076T
Other languages
English (en)
Inventor
Arnon Rosenthal
Michael Leviten
Original Assignee
Annexon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon, Inc. filed Critical Annexon, Inc.
Publication of SI3019240T1 publication Critical patent/SI3019240T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
SI201432076T 2013-07-09 2014-07-09 Protitelesa proti komplementnemu faktorju C1q in njihova uporaba SI3019240T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361844369P 2013-07-09 2013-07-09
US201361871813P 2013-08-29 2013-08-29
EP14822371.2A EP3019240B1 (en) 2013-07-09 2014-07-09 Anti-complement factor c1q antibodies and uses thereof
PCT/US2014/046042 WO2015006504A1 (en) 2013-07-09 2014-07-09 Anti-complement factor c1q antibodies and uses thereof

Publications (1)

Publication Number Publication Date
SI3019240T1 true SI3019240T1 (sl) 2024-07-31

Family

ID=52280583

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201432076T SI3019240T1 (sl) 2013-07-09 2014-07-09 Protitelesa proti komplementnemu faktorju C1q in njihova uporaba

Country Status (23)

Country Link
US (7) US20160159890A1 (sl)
EP (3) EP4252769A3 (sl)
JP (2) JP6462680B2 (sl)
KR (1) KR102321320B1 (sl)
CN (1) CN105682740B (sl)
AU (1) AU2014287221C1 (sl)
BR (1) BR112016000106B1 (sl)
CA (1) CA2916521C (sl)
DK (1) DK3019240T3 (sl)
EA (1) EA037325B1 (sl)
ES (1) ES2978917T3 (sl)
FI (1) FI3019240T3 (sl)
HK (1) HK1225678A1 (sl)
HU (1) HUE066722T2 (sl)
IL (1) IL243506B (sl)
MX (2) MX2015017341A (sl)
MY (1) MY175896A (sl)
NZ (1) NZ715455A (sl)
PL (1) PL3019240T3 (sl)
PT (1) PT3019240T (sl)
SG (3) SG11201510316UA (sl)
SI (1) SI3019240T1 (sl)
WO (2) WO2015006504A1 (sl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9480658B2 (en) 2005-12-09 2016-11-01 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
WO2007070375A2 (en) 2005-12-09 2007-06-21 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
CN104870475B (zh) 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
CA2889197A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
EP2997045A4 (en) * 2013-05-15 2016-11-23 Annexon Inc ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF
JP6462680B2 (ja) 2013-07-09 2019-01-30 アネクソン，インコーポレーテッド 抗補体因子Ｃ１ｑ抗体及びその使用
CN107207587B (zh) 2014-11-05 2022-04-19 安尼艾克松股份有限公司 人源化抗-补体因子c1q抗体及其应用
PT3280440T (pt) 2015-04-06 2023-02-14 Bioverativ Usa Inc Anticorpos anti-c1s humanizados e métodos de utilização destes
WO2016164637A1 (en) 2015-04-07 2016-10-13 Alector Llc Anti-sortilin antibodies and methods of use thereof
US10723788B2 (en) * 2015-11-24 2020-07-28 Annexon, Inc. Anti-complement factor C1q Fab fragments and uses thereof
AU2017264690A1 (en) * 2016-05-09 2018-11-29 Annexon, Inc. Compositions and methods for treating spinal muscular atrophy
CA3030872A1 (en) * 2016-07-19 2018-01-25 Annexon, Inc. Compositions and methods for treating frontotemporal dementia
EP3515932B1 (en) 2016-09-19 2023-11-22 F. Hoffmann-La Roche AG Complement factor based affinity chromatography
BR112019007309A2 (pt) * 2016-10-12 2019-07-02 Bioverativ Usa Inc anticorpos anti-c1s e métodos de uso dos mesmos
CN106699883B (zh) * 2016-12-19 2020-08-07 中国兽医药品监察所 豚鼠补体C1q-B单克隆抗体60G4的制备与应用
CN106822863A (zh) * 2017-01-04 2017-06-13 国家纳米科学中心 多肽‑抗体免疫偶联物及其制备方法
WO2018161872A1 (zh) * 2017-03-06 2018-09-13 江苏恒瑞医药股份有限公司 抗b7-h3抗体、其抗原结合片段及其医药用途
DK3687287T5 (da) * 2017-09-29 2024-08-26 Regeneron Pharma Gnavere, udtrykkende humaniseret c1q-kompleks
CN111556895B (zh) 2017-11-14 2024-09-13 中外制药株式会社 抗-c1s抗体及使用方法
EP3737472A1 (en) * 2018-01-09 2020-11-18 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie Modulators of c1q, in particular of the interaction of apoe with c1q, and uses of the modulators in the therapy of neuronal diseases and inflammation
WO2019238674A1 (en) * 2018-06-11 2019-12-19 Aarhus Universitet Single domain antibodies for complement regulation
SI3618928T1 (sl) 2018-07-13 2023-04-28 Alector Llc Protitelesa proti sortilinu in postopki za uporabo le-teh
AU2019370485A1 (en) * 2018-11-02 2021-05-13 Annexon, Inc. Compositions and methods for treating brain injury
JP2021063075A (ja) * 2019-10-16 2021-04-22 中外製薬株式会社 抗体、薬学的組成物、および方法
KR20220083737A (ko) * 2019-10-17 2022-06-20 애넥슨, 인코포레이티드 혈액 장애를 치료하기 위한 조성물 및 방법
EP4126966A4 (en) 2020-03-31 2024-08-07 Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute PROTEOMIC SCREENING FOR LYSOSOMAL STORAGE DISEASES
EP4146276A4 (en) * 2020-05-05 2024-08-14 The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone COMPOSITIONS AND METHODS FOR TREATING EPILEPSY
US20230175065A1 (en) 2020-05-08 2023-06-08 President And Fellows Of Harvard College Methods for treating inflammatory and autoimmune disorders
WO2021250323A1 (en) * 2020-06-09 2021-12-16 Helsingin Yliopisto Anti-cox-2 autoantibody as a diagnostic marker, and methods, kits and uses related thereto
WO2022081997A1 (en) * 2020-10-16 2022-04-21 Annexon, Inc. Compositions and methods for treating blood disorders
GB202113673D0 (en) * 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
EP4419144A1 (en) * 2021-10-21 2024-08-28 Annexon, Inc. Compositions and methods for treating muscular dystrophy
US20230279103A1 (en) * 2021-12-13 2023-09-07 Annexon, Inc. Anti-complement factor c1q antibodies with single binding arms and uses thereof
WO2023126821A1 (en) * 2021-12-29 2023-07-06 Curateq Biologics Private Limited C1q binding assay
WO2023130001A1 (en) * 2021-12-30 2023-07-06 Annexon, Inc. Compositions and methods for treating huntington's disease
WO2024077246A1 (en) * 2022-10-07 2024-04-11 Annexon, Inc. Formulations for anti-c1q antibodies
WO2024154122A1 (en) 2023-01-18 2024-07-25 Gilboa Therapeutics LTD Immune cells expressing a complement receptor and uses thereof

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4595654A (en) * 1983-11-07 1986-06-17 Immunomedics Inc. Method for detecting immune complexes in serum
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
ATE108068T1 (de) 1987-09-23 1994-07-15 Bristol Myers Squibb Co Antikörper-heterokonjugate zur töting von hiv- infizierten zellen.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
CA2086417C (en) 1990-06-29 1999-07-06 Biosource Technologies, Inc. Melanin production by transformed organisms
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
US20020058311A1 (en) 1995-06-13 2002-05-16 Browne Michael Jospeh Chimeric leptin fused to immunoglobulin domain and use
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
EP1516629B1 (en) * 1996-11-27 2013-04-03 Genentech, Inc. Humanized anti CD-11a antibodies
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
KR20080059467A (ko) 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
US20050197285A1 (en) 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ATE324443T1 (de) 1997-08-26 2006-05-15 Zymogenetics Inc Für adipozyten spezifische protein homologe
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20030170781A1 (en) * 1999-07-01 2003-09-11 Zymogenetics, Inc. Secreted protein zacrp4
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6781029B2 (en) 2000-07-13 2004-08-24 University Of South Florida Transgenic animal and methods
AU2002226074A1 (en) 2000-10-26 2002-05-06 Wisconsin Alumni Research Foundation. E. coli 0157:h7 c1 esterase inhibitor-binding protein stce and uses thereof
WO2002066514A2 (en) 2001-02-19 2002-08-29 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
AU2002365153A1 (en) * 2001-11-07 2003-06-30 Human Genome Sciences, Inc. 41 human secreted proteins
US20040248156A1 (en) * 2001-12-03 2004-12-09 Tianhua Hu Methods and materials relating to novel C1q domain-containing polypeptides and polynucleotides
US20050214786A1 (en) 2002-02-22 2005-09-29 Human Genome Sciences, Inc. 26 human secreted proteins
EP1556684A4 (en) 2002-11-01 2008-01-23 Univ Colorado Regents QUANTITATIVE ANALYSIS OF PROTEIN ISOFORMS USING FLIGHT TIME MASS SPECTROMETRY BY MATRIX ASSISTED LASER DESORPTION / IONIZATION
EP2266606B1 (en) 2003-05-15 2014-09-10 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
US20050019326A1 (en) * 2003-06-16 2005-01-27 The Brigham And Women's Hospital, Inc. C1q complement inhibitors and methods of use thereof
WO2005002512A2 (en) 2003-06-19 2005-01-13 University Of Rochester Immunotherapeutic vaccine strategy
US8501705B2 (en) * 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
US7544855B2 (en) 2004-04-23 2009-06-09 Buck Institute Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
CA2587143C (en) 2004-12-08 2017-12-05 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
AU2005323025A1 (en) 2004-12-31 2006-07-13 Biogen Idec Ma Inc. Polypeptides that bind BR3 and uses thereof
AU2005227420B2 (en) * 2005-10-14 2013-05-09 Alltech, Inc. Method and compositions for altering cell function
WO2007070375A2 (en) 2005-12-09 2007-06-21 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
US9480658B2 (en) 2005-12-09 2016-11-01 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
RU2429244C2 (ru) * 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
JP5695317B2 (ja) 2006-09-05 2015-04-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗体媒介性ニューロパシーを処置するための方法および組成物
CN101657097A (zh) 2007-03-01 2010-02-24 先进视觉疗法公司 以炎症为特征的疾病的治疗
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
BRPI0816785A2 (pt) 2007-09-14 2017-05-02 Adimab Inc bibliotecas de anticorpos sintéticos racionalmente desenhadas, e, usos para as mesmas
NZ586003A (en) 2007-12-11 2012-08-31 Glaxo Group Ltd Antigen binding proteins that bind beta-amyloid peptide
CA2740192C (en) 2008-12-01 2019-12-31 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detection of complement fixing antibodies
WO2010125763A1 (ja) 2009-04-28 2010-11-04 パナソニック株式会社 受信装置
KR102024922B1 (ko) 2010-07-16 2019-09-25 아디맵 엘엘씨 항체 라이브러리
WO2012067267A1 (en) 2010-11-18 2012-05-24 Takahiro Ochi TESTING METHOD USING ANTI-C1q MONOCLONAL ANTIBODY
US20140105915A1 (en) 2011-05-27 2014-04-17 Glaxo Group Limited Bcma (cd269/tnfrsf17) - binding proteins
JPWO2012176765A1 (ja) 2011-06-24 2015-02-23 株式会社ペルセウスプロテオミクス 抗ヒトｐ−カドへリン（ｃｄｈ３）遺伝子組み換え抗体
SI2794905T1 (sl) 2011-12-20 2020-08-31 Medimmune, Llc Modificirani polipeptidi za ogrodja bispecifičnega protitelesa
EP4119577A3 (en) 2012-06-18 2023-11-08 Omeros Corporation Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders
CN104870475B (zh) 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
CA2889197A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
EP2983710B1 (en) 2013-04-09 2019-07-31 Annexon, Inc. Methods of treatment for neuromyelitis optica
EP2997045A4 (en) 2013-05-15 2016-11-23 Annexon Inc ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF
JP6462680B2 (ja) 2013-07-09 2019-01-30 アネクソン，インコーポレーテッド 抗補体因子Ｃ１ｑ抗体及びその使用
CN107207587B (zh) 2014-11-05 2022-04-19 安尼艾克松股份有限公司 人源化抗-补体因子c1q抗体及其应用
US10723788B2 (en) 2015-11-24 2020-07-28 Annexon, Inc. Anti-complement factor C1q Fab fragments and uses thereof
AU2017264690A1 (en) 2016-05-09 2018-11-29 Annexon, Inc. Compositions and methods for treating spinal muscular atrophy
CA3030872A1 (en) 2016-07-19 2018-01-25 Annexon, Inc. Compositions and methods for treating frontotemporal dementia
AU2021391800A1 (en) 2020-12-04 2023-06-22 Annexon, Inc. Compositions and methods for treating ocular diseases

Also Published As

Publication number Publication date
AU2014287221B2 (en) 2019-09-12
BR112016000106B1 (pt) 2023-11-21
EA037325B1 (ru) 2021-03-12
US20200239557A1 (en) 2020-07-30
US20240083987A1 (en) 2024-03-14
EP3019240B1 (en) 2024-03-13
NZ715455A (en) 2021-12-24
US20190211084A1 (en) 2019-07-11
US10227398B2 (en) 2019-03-12
IL243506A0 (en) 2016-02-29
CA2916521C (en) 2023-03-07
SG10202008809RA (en) 2020-10-29
CN105682740B (zh) 2021-06-11
CA2916521A1 (en) 2015-01-15
IL243506B (en) 2021-07-29
US11649279B2 (en) 2023-05-16
ES2978917T3 (es) 2024-09-23
US20210277096A1 (en) 2021-09-09
SG11201510316UA (en) 2016-01-28
BR112016000106A2 (pt) 2017-12-12
CN105682740A (zh) 2016-06-15
DK3019240T3 (da) 2024-06-03
JP2019071889A (ja) 2019-05-16
EA201690182A1 (ru) 2016-10-31
HK1225678A1 (zh) 2017-09-15
HUE066722T2 (hu) 2024-09-28
KR102321320B1 (ko) 2021-11-03
EP4252769A3 (en) 2023-11-29
US20160368973A1 (en) 2016-12-22
JP2016526393A (ja) 2016-09-05
JP6462680B2 (ja) 2019-01-30
EP3019523A1 (en) 2016-05-18
PL3019240T3 (pl) 2024-08-19
JP6653009B2 (ja) 2020-02-26
AU2014287221A1 (en) 2016-01-21
MX2020010141A (es) 2020-10-20
SG10201710758PA (en) 2018-02-27
US10590190B2 (en) 2020-03-17
EP4252769A2 (en) 2023-10-04
US9708394B2 (en) 2017-07-18
EP3019240A1 (en) 2016-05-18
MX2015017341A (es) 2016-07-06
US10927167B2 (en) 2021-02-23
EP3019240A4 (en) 2017-01-04
MY175896A (en) 2020-07-14
AU2014287221C1 (en) 2020-03-05
US20170334976A1 (en) 2017-11-23
US20160159890A1 (en) 2016-06-09
WO2015006507A1 (en) 2015-01-15
EP3019523A4 (en) 2016-12-28
PT3019240T (pt) 2024-06-06
KR20160058752A (ko) 2016-05-25
FI3019240T3 (fi) 2024-05-30
WO2015006504A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
HK1225678A1 (zh) 抗-補體因子c1q抗體及其應用
IL261743B (en) and their uses 33–il antibodies against
HK1232243A1 (zh) 抗- 抗體及其用途
IL261547B (en) Antibodies against pesidine and their uses
IL245040A0 (en) Antibodies against pdgfr-beta and their uses
IL246287A0 (en) Fabs antibodies one by one and their uses
IL243974B (en) Antibodies against –prlr and uses
ZA201508896B (en) Anti-c10orf54 antibodies and uses thereof
SG11201509116VA (en) Anti-tweakr antibodies and uses thereof
EP2997045A4 (en) ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF
ZA201603596B (en) Fabs-in-tandem immunoglobulin and uses thereof